Two of the co-authors of the upgraded MASLD Clinical Practice Guidelines (CPG), Elisabetta Bugianesi and Frank Tacke join Louise Campbell and Roger Green to discuss the guidelines.
Co-authors Elisabetta Bugianesi and Frank Tacke join Louise Campbell and Roger Green to discuss the new MASLD Clinical Practice Guidelines from EASL, EASDand EASO.
In this conversation from EASL Congress 2023, Stephen Harrison, Jörn Schattenberg and Roger Green discuss the future roles of FGF-21s and incretin agonists in what was then known as NASH and NAFLD therapy.
This conversation covers some of the other major drug development stories from the EASL Congress 2024, with special focus on denifenstat, ION-224 and TAK-227, plus a look at the SPECIAL study on bariatric surgery and cirrhosis.
This conversation focuses on the role FGF-21s will play in long-term advanced fibrosis treatment: induction or long-term therapy?
This conversation explores issues regarding incretin agonists and discusses results from the efruxiermin late-breaker at the EASL Congress 2024.
This conversation focuses on the tirzepatide late-breaker at the EASL Congress 2024 and broadens into a discussion of the other “Twin-cretins,” all of which are GLP-glucagon combinations.
This conversation from EASL Congress 2024 discusses some of the new research on resmetirom.
Naim Alkhouri and Mazen Noureddin join co-hosts Jörn Schattenberg and Roger Green to discuss the major drug development stories from the EASL Congress 2024.
Roger Green conducts 1:1 interviews with Mike Betel, Louise Campbell and Sven Francque while they are at the EASL Congress 2024, discussing key issues related to MASLD
